Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation
Category: Invir.IO
High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
Tiphaine Delaunay, et al. Molecular Therapy Oncolytics, September 2020 – Read the article and view videos Publication
Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
20200908 Transgene TG6002 Phase 1 EN
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster here Poster Presentation
Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
AACR2020 6010 J. Foloppe et al. AACR 2020 Download the poster here Poster Presentation
Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
20200622b – BT-001_AACR poster EN
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a – Transgene PR AACR 3 posters
Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
20200515 BT-001_AACR curtain raiser EN
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001Marchand, Semmrich, Fend et al.Immuno-Oncology summitDownload the poster herePoster Presentation
Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
20191211 PR preclinical BT001 EN